Pharmaceutical giant Pfizer is expected to sell 50 million doses of its Covid-19 vaccine to India by the third quarter of this fiscal year as the ongoing negotiations between the company and the central government seems to be heading towards a positive conclusion.
Senior officials from the government have apparently held several discussions with senior Pfizer executives with respect to the availability of these vaccines. However, the company’s persistence towards attaining indemnity that will protect it from any sort of legal action in India has been a major stumbling block amidst the negotiations.
However, top government officers have ensured that this issue along with other matters will be clarified in the due course, Times of India reports.
The USA does not permit the export of indigenously produced Pfizer or Moderna vaccines unless Americans do not require the same. Hence, vaccination centres based in Europe are largely believed to be the source of Pfizer doses that will be delivered to India.
Meanwhile, the European Medicines Agency (EMA) has declared that the m-RNA vaccines that it has approved can neutralize the new variant that has been detected in Maharashtra. So far, the EMA has sanctioned Johnson & Johnson, Moderna, AstraZeneca and the Pfizer vaccines for the continent.